Curriculum vitae Ann M. Farese Assistant Professor, Department of Radiation Oncology University of Maryland School of Medicine Date December 19, 2013 Contact Information Business Address: Business Phone: Fax: E-mail: Education 1974 1982 1993
Department of Radiation Oncology 10 South Pine Street, MSTF 6-34D Baltimore, Maryland 21201 (410) 706-5254 (410) 706-5270 afarese@som.umaryland.edu
B.S., Medical Technology, Marquette University M.A., Management and Supervision: Health Care Administration, Central Michigan University M.S., Biology, The American University
Certifications 1974 M.T., ASCP Employment History Academic Appointments 1995-2013 Research Associate, Radiation Oncology and Pathology, UMSOM 2013-present Assistant Professor, Radiation Oncology and Pathology, UMSOM Other Employment 1974-1978 Medical Technologist-(Supervisor), VA Hospital, Durham, N.C. 1979-1983 Medical Technologist-(Hematology), Audie Murphy VA Hospital, San Antonio, TX 1983-1986 Medical Technologist- (Hematology), NIH Clinical Center, Bethesda, MD 1986-1990 Research Biologist at the Armed Forces Radiobiology Research Institute (AFRRI), Bethesda, MD 1990-1995 Research Investigator at the Armed Forces Radiobiology Research Institute (AFRRI), Bethesda, MD Professional Society Membership 1989-present General Member, International Society of Experimental Hematology 1993-2005 General Member, Society of Leukocyte Biology 1995-present General Member, American Society of Hematology 2002-2009 General Member, Society for Cell Therapy 2005-present General Member, Radiation Research Society Page 1 of 31
Ann M. Farese
2006-present
General Member, American Society of Clinical Pathologists
Administrative Service National Service 1992
Member of Personnel Review Panel, NIH, Bethesda, MD
2001
Member, Consensus Panel convened by Armed Forces Radiobiology Research Institute. Subject matter: “Large-animal Models for Radiation Injury and Countermeasures.” 5 Jun 2001. Bethesda, MD.
2003
Workshop: Radiation Working Group member and Strategic National Pharmaceutical Stockpile Program: Sponsors: CDC, FDA, DoD, DoE, NIH/NCI. “Preclinical data base in support of cytokine-treatment of Irradiated Personnel: 22 Jan 2003, Bethesda, MD.
2004
NIAID: Animal Models for Radiation Injury, Protection and Therapy Workshop. 2526 May 2004, Bethesda, MD
2004
NIAID Division of Allergy, Immunology and Transplantation (DAIT). Radiation and Nuclear Medical Countermeasure Development. Subject matter expert (SME) focused on development of models and paradigms required to define animal model protocols to be used within the FDA “Animal Rule” for approval of drugs to treat potentially lethally irradiated personnel. Multiple discussions held at NIAID throughout 2004.
2004-present
Member: Neupogen/Acute Radiation Syndrome, Nonhuman Primate Working Group. NIAID/DAIT/FDA/CDER Division of Counterterrorism.
2005-present
Co-PI of MCART contracts (2005-2010 and 2010-2015). This position requires continuous interaction with NIAID, the FDA Office of Counterterrorism and Emergency Coordination (OCTEC), the FDA Division of Medical Imaging (responsible for Radiation/Nuclear countermeasures) and the FDA Public Health Security Action Team.
2005
Member: Strategic National Stockpile Radiation Working Group Subcommittee meeting. Medical Management of high-risk febrile neutropenia consequent to acute radiation syndrome. Bethesda, MD. Feb 23, 2005.
2008
BARDA: Blood and Tissue-Related Medical Countermeasures Working Group. Panel Discussion. Feb.19, Washington, D.C.
2011
FDA, Public Health Security Action team (PHSAT). Panel Discussion on Neupogen as a MCM Against the Hematopoietic Acute Radiation Syndrome (H-ARS): The best treatment protocol available today. 27 Oct, 2011, Silver Spring, MD.
2011
FDA, Pubic Health Security Action Team (PHSAT). Panel Discussion on the Hematopoietic Acute Radiation Syndrome: Radiation quality and animal model development. 9 Nov, 2011, Silver Spring, MD.
Page 2 of 31
Ann M. Farese
2012
HHS/ASPR/BARDA/NIAID Symposium: Development of Radiation Medical Countermeasures for FDA Licensure: Lessons learned & Paths Forward. Invited Panelist; January 24, 25, 2013; Natcher Auditorium, Rockville, MD.
Reviewer Journals 1. Experimental Hematology 2. Haematologica 3. Bone Marrow Transplantation 4. International Journal of Radiation Biology 5. Journal of Controlled Release 6. European Journal of Haematology 7. Molecular Therapy 8. Biosimilars Grants-Contracts 1. Defense Threat Reduction Agency (DTRA): Radiation Biology Teaching Service 1995-present
2006-present
Quarterly in-house training for the proper handling and treatment of immunecompromised non-human primates and lectures regarding interpretation of hematopoietic and flow cytometry analysis. Monthly In-house GLP and SOP training
Undergraduate Student Teaching 1996 Mentor, Summer Research Training Program 1 undergraduate, Mr. Rigoberto Sanchez daily contact for the summer Outcome: Ph.D., Research Facilities Operation Manager, Veterinary Resources, University of Maryland. 2004 Mentor, Summer Research Training Program 1 undergraduate, Kevin P. Carter, daily contact for the summer Outcome: M.D., Assistant Professor, Family Medicine, University of Maryland. 2005 Mentor, The Nathan Schnaper Summer Student Research Internship Program 1 undergraduate, Valerie Davis, daily contact for the summer Outcome: Medical School, Temple University, Philadelphia, PA 2011 Mentor, Summer Research Training Program 1 undergraduate, Bradley Ruehle, daily contact for the summer Outcome: Undergraduate Student, UMCP 2012 Mentor, Summer Research Training Program 2 undergraduate, Bradley Ruehle and Max Ruge, daily contact for the summer Outcome: Undergraduate Student, UMCP and Boston College, respectively 2013 Mentor, Summer Research Training Program 2 undergraduate, Bradley Ruehle and Max Ruge, daily contact for the summer Outcome: Undergraduate Student, UMCP and Boston College, respectively
Page 3 of 31
Ann M. Farese
Post-Graduate Teaching 2003 Research Mentor Heme-Onc Resident National Naval Medical Center, Jennifer Crook, MD, 32 hours per week, 6 month rotation Outcome: Abstract from work performed during her tenure in our laboratory presented at 45th ASH Meeting, Dec 6-9, San Diego, CA (see co-authored abstract #77). Completed residency and fellowship, Board Certified in Internal Medicine and Hematology-Oncology, Private practice in North Falmouth, MA
Grant Support Active Grants: 09/30/10 to 09/29/15
02/11/11 to 01/10/15
(Co-Investigator: variable 70-93 %) PI: T.J. MacVittie “Medical Countermeasures Against Radiological Threats: Product Development Services” NIH/NIAID, HHSN272202000046C Current Year Annual Direct Costs: 7,425,844 Total Direct Costs: 48,141,475 (Co-Investigator: variable 7-20%) PI: T.J. MacVittie “Advanced Development of AEOL 10150 as a Medical Countermeasure for Pulmonary Injury Associated with ARS and DEARE” BARDA, HHS00100201100007C Current Year Annual Direct Costs: 2,001,976 Total Direct Costs: 34,448,270
Completed Grants: FY96 Total Funding $1,053,614 (Gift, contract) (Co-Investigator: variable %) PI: T.J. MacVittie “Comparative efficacy of soluble rhuIL-1 receptors, Type I and II in modulating the hemodynamic, metabolic and inflammatory responses in a nonhuman primate model of endotoxin shock”. Immunex Corp., (Co-Investigator: variable %) PI: T.J. MacVittie “Modulation of radiation-induced gastroenteritis consequent to conditioning for autologous bone marrow transplant.” and “Cytokine-induced recovery of thrombopoiesis following lethal radiationinduced conditioning and autologous bone marrow transplant.” Amgen, Inc., (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression.” Monsanto/G.D. Searle
Page 4 of 31
Ann M. Farese
(Co-Investigator: variable %) PI: T.J. MacVittie “Gene therapy and hematopoietic stem cell biology.” NIAID, Dr. H. Malech (Intramural funds) FY97
Total Funding $1,707,838 (Gift, contract) (Co-Investigator: variable %) PI: T.J. MacVittie “Modulation of radiation-induced gastroenteritis consequent to conditioning for autologous bone marrow transplant.” and “Cytokine-induced recovery of thrombopoiesis following lethal radiationinduced conditioning and autologous bone marrow transplant.” Amgen, Inc., (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression.” Monsanto/G.D. Searle (Co-Investigator: variable %) PI: T.J. MacVittie “Gene therapy and hematopoietic stem cell biology.” NIAID, Dr. H. Malech (Intramural funds) (Co-Investigator: variable %) PI: T.J. MacVittie “Retroviral transduction of mobilized, peripheral blood-derived hematopoietic stem cells.” Somatix
FY98
Total Funding $1,590,208 (Gift, contract) Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression or autologous bone marrow transplant: Sustained delivery filgrastim.” Amgen, Inc., (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression.” Monsanto/G.D. Searle (Co-Investigator: variable %) PI: T.J. MacVittie “Gene therapy and hematopoietic stem cell biology.” NIAID, Dr. H. Malech (Intramural funds)
FY99
Total Funding $1,055,000 (Gift, contract) (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression or autologous bone marrow transplant: Sustained delivery filgrastim.” Amgen, Inc., (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression.” Monsanto/G.D. Searle
Page 5 of 31
Ann M. Farese
FY00
Total Funding $2,489,266 (Gift, contract) (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression or autologous bone marrow transplant: Sustained delivery filgrastim.” Amgen, Inc., (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression.” Monsanto/G.D. Searle
FY01
Total Funding $1,916,000 (Gift, contract) Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression or autologous bone marrow transplant: Sustained delivery filgrastim.” Amgen, Inc., (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression.” Monsanto/G.D. Searle (Co-Investigator: variable %) PI: T.J. MacVittie “Gene therapy and hematopoietic stem cell biology.” NIAID, Dr. H. Malech (Intramural funds)
FY02
Total Funding (to date) $1,480,370 (Co-Investigator: variable %) PI: T.J. MacVittie “Cytokine-based therapeutics for radiation-induced myelosuppression.” Pharmacia Corp. (Co-Investigator: variable %) PI: T.J. MacVittie “Modulation of endotoxin-induced proinflammatory and coagulation cascade: Efficacy of humanized antibody to Factor IX.” Glaxo SmithKline
10/31/02 to 10/31/03
(Co-Investigator: variable %) PI: T.J. MacVittie “Define efficacy of Maxygen proprietary compounds in models of radiation-induced myelosuppression” Maxygen, Project ID 02434370 Annual Direct Costs: $434,094 Total Direct Costs: $434,094
05/01/03 to 06/30/08
(Co-Investigator: variable %) PI: T.J. MacVittie “Ex vivo expansion of hematopoietic stem cells” US Navy Contract, Project ID 02527758 Annual Direct Costs: $496,636 average Total Direct Costs: $2,483,182
09/15/03 to 09/14/05
(Co-Investigator: variable %) PI: T.J. MacVittie “Radiolabeled adult stem cells for in vivo migration studies”
Page 6 of 31
Ann M. Farese
DOE FY 03-04 DE-FG02-02ER6347 Annual Direct Costs: $148,263 average Total Direct Costs: $296,526 11/29/04 to 12/31/05
(Co-Investigator: 30%) PI: T.J. MacVittie “Pharmacokinetic and Pharmacologic Evaluation of G-CSF Receptor (R) Agonist.” Affymax, Inc. Project ID 02435854 Annual Direct Costs: $214,165 Total Direct Costs: $214,165
03/02/04 to 03/01/07
(Co-Investigator: variable %) PI: T.J. MacVittie “Defining the full potential of rHuGM-CSF in the post nuclear accident environment” Berlex Laboratories, Inc. Project ID 02435672 Annual Direct Costs: $34,147 average Total Direct Costs: $102,441
09/30/05 to 09/29/10
(Co-Investigator: variable %) PI: T.J. MacVittie “Medical Countermeasures Against Radiological Threats: Product Development Services” NIH/NIAID, HHSN266200500043C Annual Direct Costs: $ 7,772,350 Total Direct Costs: $38,861,751
12/22/05 to 06/30/07
(Co-Investigator: variable %) PI: T.J. MacVittie “The Pharmacology of Pegylated GM-CSF Administered After Autologous Bone Marrow Stem Cell Transplantation in the Rhesus Macaque.” Cangene Corp., Project ID 10000010 Annual Direct Costs: $35,020 average Total Direct Costs: $70,040
12/01/06 to 02/01/09
(Co-Investigator: variable %) PI: T.J. MacVittie “The Pharmacokinetics and Pharmacology of pegylated GM-CSF Administered to Normal and Myelosuppressed Rhesus Macaques.” Cangene Corp., Project ID 10001418 Annual Direct Costs: $ 85,085 average Total Direct Costs: $255,256
07/28/08 to 12/31/09
(Co-Investigator: 7 %) PI: T.J. MacVittie “The Use of Mesenchymal Stem Cells as a Radiation Countermeasure to Treat Radiation-Induced Gastrointestinal Syndrome DOD Grant with Osiris, Inc. Annual Direct Costs: $203,107 Total Direct Costs: $203,107
02/01/09 to 05/15/10
(Co-Investigator: variable %) PI: T.J. MacVittie “The Pharmacology of Aeolus 10150 Administered after TLI in Rhesus Macaques
Page 7 of 31
Ann M. Farese
Aeolus Corp. Corporate Sponsor Annual Direct Costs: $203,107 Total Direct Costs: $203,107 Publications Peer-reviewed journal articles 1. Gruber, D.F., Farese, A.M. (1989) Bone marrow myelopoiesis in rats after 10%, 20%, or 30% thermal injury. J. Burn Care & Rehab. 10:410-417. 2. Gruber, D.F., Farese, A.M. (1989) Tropism of canine neutrophils to xanthine oxidase. Am. J. Vet. Res. 50:1102-1105. 3. Gruber, D.F., O'Halloran, K.P., Farese, A.M. (1989) Xanthine oxidase potentiation of reactive oxygen intermediates in isolated canine peripheral neutrophils. J. Bio. Res. Mod. 8:462-467. 4. Gruber, D.F., O'Halloran, K.P., Farese, A.M. (1989) Aminophylline induced oxidative metabolism in isolated canine polymorphonuclear leukocytes. Immunopharm. and Immunotoxicol. 11:151-163. 5. Gruber, D.F., O'Halloran, K.P., D'Alesandro, M.M., Farese, A.M. (1990) Hypermetabolic priming of canine polymorphonuclear leukocytes by 7S-nerve growth factor. Am. J. Vet. Res. 51:921-923. 6. Eichacker, P.Q., Hoffman, W.D., Farese, A., Banks, S.M., Kuo, G.C., MacVittie, T.J., Natanson, C. (1991) Tumor necrosis factor but not interleukin-1 challenges in canines simulate the cardiopulmonary injury of human septic shock. J Appl. Physiol. 71:19791989. 7. Eichacker, P.Q., Farese, A., Hoffman, W.D., Banks, S., Mouginis, T., Richmond, S., Kuo, G.C., MacVittie, T.J., Natanson, C. (1991) Leukocyte CD11b/18 antigen directed monoclonal antibody improves early survival and decreases hypoxemia in canines challenged with tumor necrosis factor. Am. Rev. Resp. Dis. 146:1023-1029. 8. Williams, D.E., Farese, A.M., Dunn, J., Park, L.S., Frieden, E., Seiler, F.R., MacVittie, T.J. (1993) A GM-CSF/IL-3 fusion protein promotes neutrophil and platelet recovery in sublethally irradiated rhesus monkeys. Biotechnology Therapeutics, 4:17. 9. Eichacker, P.Q., Hoffman, W.D., Farese, A., Danner, R.L., Suffredini, A.F., Waisman, Y., Banks, S., Mouginis, T., Wilson, L., Rothlein, R., Elin, R.J., Hosseini, J.M., MacVittie, T.J., Natanson, C. (1993) Leukocyte CD18 monoclonal antibody worsens endotoxemia and cardiovascular injury in canines with septic shock. J. Appl. Physiol. 74:1885-92. 10. Farese, A.M., Williams, D.E., Seiler, F.R., MacVittie, T.J. (1993) Combined protocols of cytokine therapy with IL-3 and GM-CSF, in a primate model of radiation-induced marrow aplasia. Blood 82:3012-3018. 11. MacVittie, T.J., Farese, A.M., Patchen, M.L., Myers, L.A. (1994) Therapeutic efficacy of recombinant interleukin-6 alone and combined with recombinant human interleukin-3 in a nonhuman primate model of high dose, sublethal radiation-induced marrow aplasia. Blood 84: 2515-2522. 12. Eichacker, P.Q., Waisman, Y., Natanson, C., Farese, A., Hoffman, W.D., Banks, S.M., MacVittie, T.J., (1994) Cardiopulmonary effects of granulocyte colony stimulating factor in a canine model of bacterial sepsis. J Appl. Physiol. 77:2366-2373.
Page 8 of 31
Ann M. Farese
13. 14.
15. 16.
17. 18.
19.
20.
21.
22.
23.
Farese, A.M., Myers, L.A., MacVittie, T.J. (1994) Therapeutic efficacy of recombinant human leukemia inhibitory factor in a primate model of radiation-induced marrow aplasia. Blood 84: 3675-3678. Hunt, P., Li, L., Nichol, J.L., Hokom, M.M., Bogengerger, J. M., Swift, S. E., Skrine, J. D., Hornkohl, A. C., Lu, H., Clogston, C., Merewether, L. A., Johnson, M. J., Parker, V., Garcia, A., Farese, A., Hsu, R. Y., Garcia, A., Stead, R., Bosselman, R. A., Bartley, T. D. (1995) Purification and biological characterization of plasma-derived megakaryocyte growth and development factor (MGDF). Blood 86:540-547. Farese, A.M., Hunt P., Boone, T., MacVittie, T.J. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal primates. Blood 86:54-59. Farese, A.M., Herodin, F., McKearn, J.P., Baum, C., Burton, E., MacVittie, T.J. (1996) Acceleration of hematopoietic reconstitution using the synthetic cytokine, SC-55494 (a high affinity IL-3 receptor agonist) following radiation-induced, bone marrow aplasia. Blood 87:581-591. MacVittie, T.J., Farese, A.M., Herodin, F., Baum, C., McKearn, J.P. (1996) Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine (SC-55494) and rhG-CSF. Blood 87:4129-4135. Farese, A.M., Hunt, P., Grab, L. B., MacVittie, T. J. (1996) Enhancement of hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia by the combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony stimulating factor. J Clin Inves 97:21452151. Farese, A. M., MacVittie, T. J., Lind, L. B., McKearn, J. P. (1998) The combined administration of daniplastim and Mpl-Ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression. Stem Cells 16 (Suppl 2):143-154. MacVittie, T.J., Farese, A. M., Davis, T. A., Lind, L. B., McKearn, J. P. (1999) Myelopoietin, a chimeric agonist of human IL-3 and G-CSF receptors mobilizes more CD34+ cells and hematopoietic clonogenic cells in normal nonhuman primates relative to control growth factors: MPO mobilized CD34+ cells rapidly engraft lethally x-irradiated autologous hosts. Exp Hematol 72:1557-1568. Rosenzweig, M., MacVittie, T.J., Harper, D., Hempel, D., Glickman, R. L., Johnson, R. P., Farese, A.M., Whiting-Theobald, N., Linton, G.F., Yamasaki, G., Jordan, C.T., Malech, H.L. (1999) Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates. Blood 94:2271-2286. MacVittie, T.J., Farese, A. M., Lind, L. B., Baum, C. M., Burton, E., McKearn, J. P. (2000) Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood 95:837-845. MacVittie, T.J., Farese, A. M., Davis, T. A., Lind, L. B., McKearn, J. P. (2000) Myelopoietin, a chimeric agonist of human interleukin-3 and granulocyte colonystimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally xirradiated nonhuman primates. Exp. Hematol 27:1557-1568.
Page 9 of 31
Ann M. Farese
24.
25.
26.
27.
28.
29. 30. 31.
32.
33.
34.
King, A., Horowitz, D., Dillon, S., Levin, R., Farese, A., MacVittie, T., Pelus, L. (2001) Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in Rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GROβ. Blood, 97:1534-1542. Zamboni, W.C., D’Argenio, D.Z., Stewart, C.F., MacVittie,T.J., Delauter, B.J., Farese, A.M., Potter, D.M., Kubat, N.M., Tubergen, D., Egorin, M.J. (2001) Pharmacodynamic model of topeotecan-induced time course of neutropenia. Clin Cancer Res, 7(8):23012308. Farese, A.M., Smith, W.G., Giri, J.G., Seigle, N., McKearn, J.P., MacVittie, T.J. (2001) Promegapoietin, an engineered chimeric IL-3 and mpl-L receptor agonist stimulates hematopoietic recovery in an abbreviated schedule following radiation-induced myelosuppression in nonhuman primates. Stem Cells, 19:329-338. Farese, A.M., Casey, D.B., Smith, W.G., Vigneulle, R.M., McKearn, J.P., MacVittie, T.J. (2001) Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: Effect of schedule, dose and route of administration. Stem Cells, 19:522-533. Farese, A.M., Casey, D.B., Vigneulle,R.M., Siegel, N.R., Finn, R.F., Klover, J.A., Smith, W.G., McKearn, J.P., MacVittie, T.J. (2001) A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells 19:514-521. MacVittie, T. J., Farese, A. M., (2002) Cytokine-based treatment of radiation-injury: Is there a potential benefit following low level radiation exposure. J. of Military Medicine167, Suppl. 1:068-070. Farese, A.M., MacVittie, T.J., Roskos, L., Stead, R. B. (2003) Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: Effect of variation in treatment schedule with PEG-rHuMGDF. Stem Cells 21:79-89. Smith, D.E, Hanna, R., Friend, D., Moore, H., Chen, H, Farese, A.M, MacVittie, T.J., Virca, G.D., Sims, J.E., (2003) The soluble form of IL-1 receptor accessory protein is abundant in normal serum and enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18:87-96. Cross, A.S., Sakarya, S., Rifat, S., Held, T.K., Drysdale, B.E., Grange, P.A., Cassels, F.J., Wang, L.X., Stamatos, N., Farese, A., Casey, D., Powell, J., Bhattacharjee, A.K., Kleinberg, M., Goldblum, S.E., (2003) Recruitment of murine neutrophils in vivo through endogenous sialidase activity. J. Biological Chemistry 278:4112-4120. Farese, A.M., Yang, B-B., Roskos, L., Stead, R.B., MacVittie, T.J. (2003) Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplantation 32:399-404 Poliakova, L., Pirone, A.T., Farese, A.M., MacVittie, T.J., Farney, A. (2004) Presence of nonhematopoietic side population cells in the adult human and non-human primate pancreas. Transplantation Proceedings 36:399-404.
Page 10 of 31
Ann M. Farese
35.
36. 37. 38.
39.
40. 41.
42. 43.
44.
45. 46.
Koopman, G., Niphuis, J., Haaksma, A.G., Farese, A.M., Casey, D.B., Kahn, L.E., Mann, D., MacVittie, T.J., Woulfe, S.L., Heeney, J.L. (2004) Increase in plasmacytoid and myeloid dendritic cells by progenipoietin-1, a chimeric Flt-3 and G-CSF receptor agonist, in SIV-infected rhesus macaques. Hum Immunol. 65(4):303-16. Yusibov, V., Mett, V., Mett, V., Davidson, C., Musiychuk, K., Gilliam, S., Farese, A., MacVittie, T., Mann, D.(2005) Peptide-based candidate vaccine against respiratory syncytical virus. Vaccine 23:2261-65. MacVittie T.J., Farese A.M., Jackson, W. 3rd. (2005) Defining the Full Therapeutic Potential of Recombinant Growth Factors in the Post Radiation-Accident Environment: The effect of supportive care plus administration of G-CSF. Health Phys. 89(5):546-55. Koopman G, Mortier D, Niphuis H, Farese AM, Kahn LE, Mann D, Wagner R, Macvittie TJ, Woulfe SL, Heeney JL. (2005) Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy. Vaccine. 2005 May 13. Sebastian B., Ryser, M.F., Choi, U., Whiting-Theobald, N., Kuhlisch, E., Linton, G., Kang, E., Lehmann, R., Roesler, J., Rosen-Wolff, A., Rudikoff, A.G., Farese, A.M., MacVittie, T.J., Horwitz, M.E., Malech, H.L. (2006) Polyclonal long-term MFGSgp91phox marking in rhesus macaques after non-myeloablative transplantation with transduced autologous peripheral blood progenitor cells. Molecular Therapy, 14(2):20211. Cheng X, Macvittie T, Meisenberg B, Welty E, Farese A, Tadaki D, Takebe N. (2007) Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact. Growth Factors. Jun;25(3):141-50. Ossetrova, N.I., Farese, A.M., MacVittie, T.J., Manglapus, G.L., Blakely, W.F. (2007) The use of discriminant analysis for evaluation of early-response multiple biomarkers of radiation exposure using non-human primate 6-Gy whole-body radiation model. Radiation Measurements. Radmeas:42(6-7) 1158-1163. Cheng, X., MacVittie, T., Meisenberg, B., Welty, E., Farese, A.M., Tadaki, D., Takebe, N. (2007) Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact. Growth factors (Chur, Switzerland), 25(3):141-50. Harris, K.M., Lenz, P., Hankey, K.G., MacVittie, T., Farese, A., Nakajima, K., Hasumi, K., Mann, D. L. (2008) Products of anti-DC3/anti-CD28 activated lymphocytes induce differentiation and maturation of dendritic cells and has adjuvant-like activity in vitro and in vivo. Clinical Immunology 129(1):58-68. Farese, A.M., Cohen, M.V., Stead, R.B., Jackson III, W., MacVittie, T.J. (2012) Pegfilgrastim, administered in an abbreviated schedule, significantly improves neutrophil recovery after high-dose, radiation-induced myelosuppression in rhesus macaques. Rad Research, 178(5):403-13. Farese, A.M., Cohen, M.V., Katz, B. P, Smith, C. P. Jackson III, W., Cohen, D.M., MacVittie, T.J. (2012) A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management. J Health Phys, 103(4):367-382. MacVittie, T.J., Farese, A.M., Bennett, A., Gelfond, D., Shea-Donohue, T., Tudor, G., Booth, C., McFarland, E., Jackson III, W. (2012) The Acute Gastrointestinal SubSyndrome of the Acute Radiation Syndrome: A rhesus macaque model. J Health Phys, 103(4):411-426.
Page 11 of 31
Ann M. Farese
47.
48.
49. 50.
51. 52.
53.
54.
MacVittie, T.J., Bennett, A., Booth, C., Garofalo, M., Tudor, G., Ward, A., SheaDonohue, T., Gelfond, D., McFarland, E., Jackson III, W., Lu, W., Farese, A.M., (2012) The prolonged gastrointestinal syndrome in rhesus macaques: the relationship between gastrointestinal, hematopoietic, and delayed multi-organ sequelae following acute, potentially lethal, partial-body irradiation. J Health Phys, 103(4):417-453. Plett, P.A., Sampson, C.H., Chua, H.L., Joshi, M., Booth, C., Gough, A., Johnson, C. S., Katz, B.P., Farese, A.M., Parker, J., MacVittie, T.J., Orschell, C. M. (2012) Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome J Health Phys, 103(4):343-355. Farese, A.M., Cohen, M.V., Katz, B. P, Smith, C. P. Gibbs, A.M., Cohen, D.M., MacVittie, T.J. (2013) Filgrastim improves survival in lethally irradiated nonhuman primates. Rad Research, 179(1):89-100. Farese, A.M., Brown, C.R., Smith, C. P. Gibbs, A.M., Katz, B. P, Johnson, C.S., Prado, K., MacVittie, T.J. (2014) The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent. J Health Phys 106(1):39-47. MacVittie, T.J., Bennett, A., Cohen, M.V., Farese, A.M., Higgins, A., Hankey, K.G., (2014) Immune Cell Reconstitution After Exposure to Potentially Lethal Doses of Radiation in the Nonhuman Primate. J Health Phys 106(1):84-96. Garofalo, M.C., Bennett, A., Farese, A.M., Ward, A.A., Taylor-Howell, C., Cui, W., Gibbs, A., Lasio, G., Jackson, W., MacVittie, T.J. (2014) The delayed pulmonary syndrome following acute high-dose irradiation: A rhesus macaque model. J Health Phys 106(1):56-72. Garofalo, M.C., Ward, A.A., Farese, A.M., Bennett, A., Taylor-Howell, C., Cui, W., Gibbs, A., Prado, K., Jackson, W., MacVittie, T.J. (2014) A Pilot Study in Rhesus Macaques to Assess the Treatment Efficacy of a Small Molecular Weight Catalytic Metalloporphyrin Antioxidant (AEOL 10150) in Mitigating Radiation-Induced Lung Damage. J Health Phys 106(1):73-83. Dörr, H., Lamkowski, A., Gräßle, D., Bennett, A., Shapiro, A., Farese, A.M., Garofalo, M., MacVittie, T.J., Meineke, V. (2014) Linking the Human Response to Unplanned Radiation and Treatment to the Nonhuman Primate Response to Controlled Radiation and Treatment. J Health Phys 106(1):129-134.
Non-peer reviewed journal article 1. Farese, A.M., MacVittie, T.J., Schiffer, C. (1997) The impact of thrombopoietin and related Mpl-Ligands on transfusion medicine. Transfusion Medicine Review. 11:243255. Book Chapters or Proceedings 1. MacVittie, T.J., Monroy, R.L., Farese, A.M., Patchen, M.L., Seiler, F.R., Williams, D. (1991) Cytokine therapy in canine and primate models of radiation-induced marrow aplasia. Rizzoli, V., Schulz, G., and Seiler, F.R. eds. Behring Inst. Mitt. 90:1-13 2. Farese, A. M. and MacVittie, T.J. (1996) Efficacy of MPL ligand and other thrombopoietic cytokines in animal models. Kuter, D., Hunt, P., Sheridan, W. P., eds. IN: The molecular, cellular, and clinical biology of the platelet-stimulating factors. Humana Press.
Page 12 of 31
Ann M. Farese
3.
4.
5. 6.
MacVittie, T.J. and Farese, A.M. (2001) Cytokine-based treatment for acute radiationinduced myelosuppression: Preclinical and clinical perspective. Ricks, R.C., Berger, M.E., O’Hara, Jr., F. M ed. IN: The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims, The Parthenon Publishing Group, Pearl River, NY. pp 5372.3. MacVittie, T.J. and Farese, A.M. (2003) New directions in growth factor therapy. Dainiak, N., Waselenko, J.K., Armitage, J., MacVittie, T.J., and Farese, A. M. ed. IN: The hematologist and radiation casualties. The American Society for Hematology Education Program Book, Washington, D.C. Farese, A. M., MacVittie, T.J. (2003) Hematopoietic growth factors: preclinical studies of myeloid and immune reconstitution. Morstyn, G., Foote, M.A., Leishchke, G., eds. IN: Hematology growth factors for oncology. Humana Press. Totowa, NJ. pp 185-207. Farese, A.M., Cohen, M.V., MacVittie, T.J. (2012) G-CSF enhances recovery and survival from severe radiation-induced myelosuppression. Molineux, G., Arvedson, T. and Foote, M.,eds. IN: Twenty Years of G-CSF, Milestones in Drug Therapy, Part 3, 365-380, Springer Basel AG, Switzerland.
Abstracts: Primary Author Presentations 1. Farese, A., Eichacker, P., Patchen, M., Bowles, C., Danner, R., Natanson, C., MacVittie, T. (1990) Gram negative hyperdynamic sepsis in the canine: systemic and pulmonary neutrophil kinetics and functions. 19th Annual Meeting, ISEH, Seattle, WA. Experimental Hematology. 18:697. 2. Farese, A., Eichacker, P., Patchen, M., Eichenholtz, P., Natanson. C., MacVittie, T. (1990) In vivo infusion of recombinant human TNF in normal canines effects the number and function of circulating neutrophils. FASEB Washington, DC. The FASEB Journal. 4:A524. 3. Farese, A., Eichacker, P., Patchen, M., Natanson, C., MacVittie, T. (1991) Gram negative hyperdynamic sepsis in the canine: systemic and pulmonary neutrophil kinetics and functions. 2nd International Congress on the Immune Consequences of Trauma, Shock, and Sepsis. Mar. 6-9, Munich, Germany. 4. Farese, A.M., McLaughlin, E.K., Tropea, M.M., Andersen, T., MacVittie, T.J. (1992) In vitro effects of recombinant human IL-1, IL-8 and TNF on canine neutrophil function. The 2nd Conference on The Immunocompromised Surgical Patient: Mechanisms and Therapy in Trauma and Burns. Jan 26-29, Snowbird, Utah. 5. Farese, A.M., McLaughlin, E.K., Kirschner, K.F., Nash, R., MacVittie, T.J. (1992) Stimulation of canine neutrophils by recombinant human interleukin-8 (rhIL-8) or phorbol 12-myristate 13-acetate (PMA) following in vivo administration of either recombinant canine granulocyte (rcG-CSF) or granulocyte-macrophage colonystimulating factor (rcGM-CSF). (1992) 21st Annual Meeting of the International Society for Experimental Hematology. July 26-30, Providence, RI. 6. Farese, A.M., McLaughlin, E.K., Eichacker, P.Q., Natanson, C., MacVittie, T.J. (1993) Stimulation of canine nuetrophils by rhIL-8 or phorbol 12-myristate, 13-acetate following the prophylactic administration of rcG-CSF before and after the induction of gram negative sepsis. Keystone Symposia on Molecular and Cellular Biology. Cytokines and Cytokine Receptors:From Cloning to the Clinic. Jan 31-Feb 7, Keystone, CO.
Page 13 of 31
Ann M. Farese
7.
8.
9.
10.
11.
12.
13.
14.
15.
Farese. A.M., Kirschner, K.F., Patchen, M.L., Zsebo, K.M., MacVittie, T.J. (1993) The effect of recombinant canine stem cell factor and/or recombinant canine granulocyte colony stimulating factor on marrow aplasia recovery in lethally irradiated canines. 22nd International Meeting of the Society for Experimental Hematology. Aug 22-27, Rotterdam, The Netherlands. Exp Hematol. 21:585a,1169. Farese, A.M., Myers, L.A., MacVittie, T.J. (1994) Therapeutic efficacy of recombinant human leukemia inhibitory factor relative to the interleukins 6 and 3 in a nonhumanprimate model of radiation-induced marrow aplasia. 23rd Annual Keystone Symposia on Molecular and Cellular Biology. Hematopoiesis. Jan 4-11, Breckenridge, CO. The Journal of Cellular Biochemistry Suppl 18A, 34. Farese, A.M., Myers, L.A., MacVittie, T.J. (1994) Therapeutic efficacy of the combined administration of either recombinant human interleukin-6 and rh-granulocyte colony stimulating factor or rh-granulocyte-macrophage colony stimulating factor in a primate model of radiation-induced marrow aplasia. 23rd International Meeting of the Society of Experimental Hematology. Aug 21-25, Minneapolis, MN. Exp Hematol. 22:27a, 684. Farese, A.M., Herodin, F., Grab, L.A., Varma, N., Baum, C., Burton, E., McKearn, J.P., MacVittie, T.J. (1994) Therapeutic efficacy of synthokine SC-55494 in a nonhuman primate model of high dose, sublethal, radiation-induced marrow aplasia.The 36th Annual Meeting of the American Society of Hematology. Dec 3-7, Nashville, TN. Blood 84:Suppl 1, 28a,102. Farese, A.M., Hunt, P., Grab, L.B., Matlick, D.R., MacVittie, T.J. (1995) Modulation of megakaryocytopoiesis in normal and sublethally irradiated nonhuman primates by recombinant human megakaryocyte growth and development factor (r-HuMGDF). American Society for Bone Marrow Transplantation. Jan 26-28, Keystone, CO. Farese, A.M., Hunt, P., Grab, L.B., MacVittie, T.J. (1995) Enhancement of hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia by the combined administration of Recombinant human megakaryocyte growth and development factor and granulocyte colony stimulating factor. The 24th Annual Meeting of the International Society for Experimental Hematology, Aug 27-31, Dusseldorf, Germany. Exp Hematol 23:520a, 901. Farese, A.M., Hunt, P., Grab, L.B., MacVittie, T.J. (1995) Evaluation of administration protocols of pegylated-megakaryocyte growth and development factor on platelet recovery in a primate model of radiation-induced bone marrow aplasia. 37th Annual Meeting for the American Society of Hematology. Dec 1-5, Seattle, WA. Farese, A.M., Hunt, P., Grab, L.B., MacVittie, T.J. (1996) Efficacy of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) alone and in combination with recombinant human granulocyte colony stimulating factor (rhG-CSF) in irradiated nonhuman primates. The Immunocompromised Surgical Patient: Mechanisms and Therapy in Trauma and Burns. Jan 21-24, Snowbird, UT. Farese, A.M., Grab L.B., Vigneulle, R.M., Dacquel, L., Stead, R.B., MacVittie, T.J., (1996) Therapeutic efficacy of PEG-rHuMGDF in a nonhuman primate model of myeloablation with autologous bone marrow transplantation. 4th International Symposium of Recent advances in hematopoietic stem cell transplantation. Apr 11-13, San Diego, CA
Page 14 of 31
Ann M. Farese
16.
17.
18.
19.
20.
21.
22.
23.
24.
Farese, A.M., Stead, R.B., Roskos, L., Lind, L.B., Cheung, E., Vigneulle, R.M., Ritchey, B., MacVittie, T.J. (1996) Hematopoietic recovery following autologous bone marrow transplantation: Effect of pretreatment and/or therapeutic administration of PEGrHuMGDF. 38th Annual Meeting for the American Society of Hematology, Dec 6-10, Orlando, FL. Blood 88:600a, 1996. Farese, A.M., Lind, L.B., Giri, J.G., Kahn, L., McKearn, J.P., MacVittie, T.J. (1997) A single dose of promegapoietin stimulates platelet recovery similar to a daily or an abbreviated administration schedule following myelosuppression in nonhuman primates. Keystone Symposia on Molecular and Cellular Biology, Hematopoiesis, Feb 10-17, Tamarron, CO. Farese, A.M., Nash, R., MacVittie, T.J. (1997) The stimulation of canine neutrophils by recombinant human interleukin-8 or phorbol 12-myristate 13-acetate (PMA) following in vivo administration of either recombinant canine granulocyte (rcG-CSF) or granulocytemacrophage colony stimulating factor (rcGM-CSF). 19th Annual Phagocyte Workshop, April 25, Washington, D.C. Farese, A.M., MacVittie, T.J., Lind, L.B., McKearn, J.P. (1997) The combined administration of daniplestim and Mpl-Ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression. 39th Annual Meeting for the American Society of Hematology, Dec. 5-9, San Diego, CA. Blood 90:185b, 3554. Farese, A.M., MacVittie, T.J., Lind, L.B., Stead, R.B. (1997) Hematopoietic recovery following autologous bone marrow transplantation: Effect of an abbreviated, high dosage administration schedule of PEG-rHuMGDF. 39th Annual Meeting for the American Society of Hematology, Dec. 5-9, San Diego, CA. Blood 90:94a, 411. Farese, A.M., Smith, W.G., McKearn, J. P. MacVittie, T.J. (1998) Progenipoietin-G, an engineered chimeric agonist for flt-3 and G-CSF receptors stimulates multilineage hematopoietic recovery following radiation-induced myelosuppression. International Conference on Diagnosis and Treatment of Radiation Injury, 31 Aug- 3 Sept. Rotterdam, The Netherlands Farese, A.M., MacVittie, T.J., Dacquel Smith, L., Smith, W.G., Woulfe, S.L. (1998) Progenipoietins, chimeric agonists of Flt-3 and the G-CSF receptors, stimulate multilineage hematopoietic recovery in myelosuppressed nonhuman primates. 40th Annual Meeting for the American Society of Hematology, Dec 4-8, Miami, Fl. Blood 92:507a Farese, A.M., Roskos, L., Cheung, E., Stead, R.B., Yin, S.M., MacVittie, T.J. (1998) A single administration of r-metHuG-CSF-SD-01 (SD/01) significantly improves neutrophil recovery following autologous bone marrow transplantation. 40th Annual Meeting for the American Society of Hematology, Dec 4-8, Miami, Fl. Blood 92:112a Farese, A.M., Roskos, L., Cheung, E., Stead, R.B., Yin, S.M., MacVittie, T.J. (1999) A single administration of r-metHuG-CSF-SD-01 (SD/01) significantly improves neutrophil recovery following autologous bone marrow transplantation. American Society for Bone Marrow Transplantation. Feb 28-Mar 6, Keystone, CO.
Page 15 of 31
Ann M. Farese
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Farese A.M., Smith, W.G., Casey, D.B., Vigneulle, R.M., Oshetski, J.A., Cogburn, J.N., MacVittie, T.J., McKearn, J.P. (1999) An abbreviated schedule of leridistim, a multifunctional agonist of IL-3 and G-CSF receptors, induces multilineage recovery in a non-human primate myelosuppression model. 28th Annual Meeting of the International Society for Experimental Hematology, July 10-14, Monte Carlo, Monaco. Exp Hematol 27:97, abstract 231. Farese, A.M., Casey, D.B., Vigneulle, R. M., Smith, W.G., Woulfe, S. L., MacVittie, T.J. (1999) Progenipoietin, in an abbreviated (QOD) schedule, stimulates superios multilineage hematopoietic recovery as compared to Flt-3L and/or G-CSF. 41th Annual Meeting for the American Society of Hematology, Dec 3-7, New Orleans, LA Blood 94:48a, abstract 200. Farese, A. M., Roskos, L., Stead, R. B., MacVittie, T. J. (1999) r-metHuG-CSF-SD-01 (SD/01) significantly improves neutrophil recovery in myelosuppressed nonhuman primates. 41th Annual Meeting for the American Society of Hematology, Dec 3-7, New Orleans, LA Blood 94:49a, abstract 204. Farese, A.M., Casey, D.B., Vigneulle, R. M., Siegel, N.R., Finn, R.F., Smith, W.G.,McKearn, J.P., MacVittie, T.J. (2000) A single dose of Peg-leridistim Stimulates multi-lineage hematopoietic recovery in sublethally irradiated nonhuman primates. 42nd Annual Meeting for the American Society of Hematology, Dec 1-6, San Francisco, CA. Blood 96:295a, abstract 1272. Farese, A.M., Redinger, C.J., Casey, D.B., Kahn, L.E., Fox, C.H., MacVittie, T. J. (2001) Progenipoietin-induced dendritic cell (DC) mobilization and collection via apheresis in normal rhesus macaques. American Association for Cancer Research, Mar 24-28, New Orleans, LA. Proceedings of the American Association for Cancer Research 12:24, abstract 132. Farese, A.M., Redinger, C.J., Woulfe, S.L., Kahn, L.E., Mann, D., Fox, C.H., MacVittie, T.J. (2002) Mobilization and in vivo expansion of dendritic cells by Progenipoietin (ProGP) in normal rhesus macaques. (2002) 7th International Symposium on Dendritic Cells, Sep 19-24, Bamberg, Germany. Farese, A.M., Jackson,III, W., MacVittie, T.J., (2007) Medical Management Used Alone is an Effective Medical Countermeasure Against the Lethal Effects of Total Body Irradiation (TBI). 10th Annual Force Health Protection Conference, Aug 4-10, Louisville, KY Farese. A.M., Bullock, K.N., Veirs, M.C., Smith, C. P., Katz, B., Juliar, B.E., MacVittie, T.J., (2007) Medical Management in Rhesus Macaques Increases Survival From the Lethal Acute, Radiation Hematopoietic Syndrome, 36th Annual Meeting of the International Society for Experimental Hematology Sep 28-30, Hamburg, Germany. Farese AM, Veirs MC, Smith CP, Katz B, Juliar BE, MacVittie TJ (2008) Medical management alone increases survival of lethally irradiated nonhuman primates within the hematopoietic syndrome, 54th Annual Meeting of the Radiation Research Society, 21-25 Sept, Boston, MA. Proceedings Abstract:PS3617, pp 110. Farese AM, Devens B, Lou L, MacVittie, TJ. (2008) Pharamcodynamic (PD) and Pharmacokinetics (PK) of a long-lasting G-CSF in a Primate Model of Radiation-Induced Neutropenia. 54th Annual Mtg of Radiation Research Society, 21-25 Sept, Boston, MA Proceedings Abstract:PS3779, pp 150.
Page 16 of 31
Ann M. Farese
35.
36.
37.
38.
Farese, A.M., Cohen, M.V., McFarland, E., Potten, C., Booth, C., MacVittie, T.J. (2009) Medical countermeasures against the acute hematopoietic and gastrointestinal (GI) syndromes. 37th Annual Meeting of the European Radiation Research Society, 26-29 Aug, Prague, CZ. Proceedings Abstract:056. Farese AM, Cohen, M.V., Gibbs, A., Smith, C.P., Katz, B., Nguyen, J., Lerma, F., MacVittie, T.J., (2009) Filgrastim Administration Significantly Improves Survival in an LD 50/60 Model of Total Body Irradiation (TBI) in Nonhuman Primates (NHP). 55th Annual Meeting of Radiation Research Society, Oct 3 -7, Savannah, GA, Proceedings Abstract: PS5.40, pp 127. Farese AM, Ruo, C, Smith, C.P., Bennett, A., Cohen, D.M., Gibbs, A.M., Katz, B., Prado, K.. Garofalo, M., O’Brien, T., Tabisz, S., Melatakos, G., Flinn, C., Flynn, M., Cui, W., Ward, A., Taylor-Howell, C., Swartz, E., MacVittie, T.J. (2012) Delayed Filgrastim Administration Does Not Improve Survival in an LD 50/60 Model of Total-Body Irradiation (TBI) in Nonhuman Primates (NHP). 58th Annual Meeting of Radiation Research Society, 29 Sept – 4 Oct, San Juan, Puerto Rico, Proceedings Abstract:PS4-28, pp101. Farese AM, Smith, C.P., Brown, CR, Bennett, A., Katz, B., Prado, K.., MacVittie, T.J. The efficacy of G-CSF to mitigate survival following LD50/60 total body irradiation (TBI) is dependent upon the timing of its initiation. (2013) ConRad 2013, the Global Conference on Radiation Topics (20th Nuclear Medical Defense Conference) May 13th – 16 Munich, GR.
Abstracts: Co-author Presentations 1. MacVittie, T.J., D'Alesandro, M.M., Monroy, R.L., Farese A.M., Patchen, M.L., Clark, S., Donahue, R. (1988) Stimulation of hematopoiesis in canines by in vivo administration of recombinant human GM-CSF (rhGM-CSF). UCLA Symposia on Molecular and Cellular Biology Growth Factors and Their Receptors: Genetic Control and Rational Application. Keystone,Colorado. Journal of Cellular Biochemistry. 12:152. 2. MacVittie, T.J., Schwartz, G.N., Vriesendorp, H., Monroy, R.L., Darden, J., Farese, A.M., Souza, L. (1988) Stimulation of granulopoiesis in normal and sublethally irradiated canines by in vivo administration of recombinant human granulocyte colony stimulating factor (rhG-CSF). 5th International Symposium on Infections in the Immuno Compromised Host, Noordivijkerhout, Netherlands. 3. MacVittie, T.J., Schwartz, G.N., Monroy, R.L., Patchen, M.L., Farese, A.M., Benjamin, W., Lomedico, P. (1988) Stimulation of hemopoiesis in canines by in vivo administration of recombinant human interleukin-1. 17th Annual Meeting-ISEH, Houston, TX. Exp. Hematol. 16:537. 4. Nold, J.B., Gruber, D.F., Heman-Ackah, Y.D., Farese, A.M., (1989) Morphometric changes in rat spleen following irradiation, thermal injury, and combined injury. 37th Annual Meeting of Radiation Research Society, Seattle, WA. Abstract EK-21. 5. Eichacker, P., Gruber, D., Mouginis, T., Hoffman, W., Banks, S., Farese, A., Richmond, S., MacVittie, T., Natanson, C.(1990) Antibody against neutrophil adhesion complex CDW18 does not improve survival or prevent cardiopulmonary abnormalities after tumor necrosis factor infusion in dogs. Critical Care Medicine's Annual Symposium, San Francisco, California. Critical Care Medicine 18:5183.
Page 17 of 31
Ann M. Farese
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Eichacker, P., Banks, S.M., Hoffman, W.D., Danner., R.L., Mouginis, T., Richmond, S., Farese, A.M., Parrillo, J.E., MacVittie, T.J., Natanson C. (1990) Pulmonary injury in a lethal canine model of human bacterial sepsis. American Foundation of Clinical Research's Annual Meeting, Washington, D.C. Clinical Research 38:260A. Eichacker, PQ., Gruber, D., Mouginis, T., Hoffman, W.D., Banks, S.M., Farese, A.M., Richmond, S., MacVittie, T.J., Natanson,C. (1990) Antibody against neutrophil adhesion complex CDW11 does not improve survival or prevent cardiopulmonary abnormalities after tumor necrosis factor infusion in dogs. American Foundation of Clinical Research's Annual Meeting, Washington, D.C. Clinical Research 38:260A. MacVittie, T.J., Farese, A.M., Patchen, M.L., Monroy, R., Souza, L.M. (1990) Combined modality protocols with recombinant human (rh)GM, rhG-CSF, and recombinant canine G-CSF (rcG-CSF) in the normal canine. 19th Annual Meeting, ISEH, Seattle, WA. Exp. Hematol. 18:660 MacVittie, T.J., Farese, A.M., Patchen, M.L., Monroy, R., Souza, L.M. (1991) Single and combined modality protocols with recombinant human (rh)GM, and rhG-CSF, and recombinant canine G-CSF (rcG-CSF) in the normal and lethally irradiated canine. 2nd International Congress on the Immune Consequences of Trauma, Shock, and Sepsis: Mechanisms and Therapeutic Approaches. Munich, Germany. March 6-9, 1991. Eichacker, P.Q., Mouginis, T., Farese, A., Hoffman, W., Banks, S.M., Suffredini, A., Waisman, H., Danner, R.L., MacVittie, T., Natanson, C. (1991) Serum tumor necrosis factor increases early and transiently in a chronic canine model of septic shock. Meeting of the American Thoracic Society, Anaheim, CA. Review of Respiratory Disease 143:A681. Eichacker, P.Q., Hoffman, W.D., Farese, A., Mouginis, T., Banks, S.M., Richmond, S., MacVittie, T.J., Natanson, C. (1991) Monoclonal antibody against leukocyte CDW11b/18 adhesion complex reduces early deaths and hypoxemia after tumor necrosis factor challenge in canines. Review of Respiratory Disease. 143:A681. Waisman, Y., MacVittie, T.J., Farese, A., Banks, S.M., Hoffman, W.D., Souza, L., Natanson, C., Eichacker, P.Q. (1991) A controlled trial of granulocyte colony stimulating factor in a canine model of human bacterial sepsis. Annual Meeting for the American Federation of Clinical Research. May, Seattle, WA. Clinical Research 39:165A. Eichacker, P.Q., Farese, A., Hoffman, W., Banks, S.M., Waisman, Y., Danner, R.L., MacVittie, T.J., Natanson, C., (1991) Alveolar neutrophils are maximal during recovery of pulmonary function in a canine model of human septic shock. Annual Meeting for the American Federation of Clinical Research. May, Seattle, WA. Clinical Research 39:453A. Williams, D.E., Farese, A., Dunn, J., Frieden, E., Park, L.S., MacVittie, T.J., (1991) In vivo effects of a GM-CSF/IL-3 fusion protein (PIXY321) in sublethally irradiated monkeys. 20th Annual Meeting for the International Society for Experimental Hematology. July 21-25, Parma, Italy. Exp. Hematol. 19:479. MacVittie, T.J., Farese, A.M., Patchen, M.L., Williams, D.E. (1991) Hematologic effects of in vivo administration of recombinant GM-CSF/IL-3 fusion protein (PIXY321) in normal primates. 20th Annual Meeting for the International Society for Experimental Hematology. July 21-25, Parma, Italy. Exp. Hematol. 19:170.
Page 18 of 31
Ann M. Farese
16.
17.
18.
19.
20.
21.
22.
23. 24.
25.
MacVittie, T.J., Waisman, Y., Farese, A.M., Natanson, C., Patchen, M.L., Souza, L.M., Eichacker, P.Q. (1992) Gram negative sepsis:Prophylaxis in a canine model using recombinant canine granulocyte colony stimulating factor (rcG-CSF). The Immunocompromised Surgical Patient: Mechanisms and Therapy in Trauma and Burns. Jan 26-29, Snowbird, Utah. MacVittie, T.J., Brandenburg, R., Farese, A.M., Patchen, M.L., Weiss, J., Scheffler, B. (1992) Enhanced recovery from supralethal radiation exposure using combined modality WR2721 plus recombinant human G-CSF. Annual Meeting for the American Association for Cancer Research. May 21-23, San Diego, CA. MacVittie, T.J., Waisman, Y., Farese, A.M., Natanson, C., Patchen, M.L., Souza, L.M., Eichacker, P.Q. (1992) Prophylaxis in a canine model of gram negative sepsis using recombinant canine granulocyte colony-stimulating factor (rcG-CSF). 21st Annual Meeting for the International Society for Experimental Hematology. July 26-30, Providence, RI. Kirschner, K.F., Kittell, C.L., Farese, A.M., Widmer, M., Williams, D.E., MacVittie, T.J. (1992) Differential expression of cytokines and tumor necrosis factor receptor (TNFR) in plasma of nonhuman primates subjected to sublethal endotoxic shock. 21st Annual Meeting for the International Society for Experimental Hematology. July 26-30, Providence, RI. MacVittie, T., Kittell, C., Kirschner, K., Farese, A., Agosti, J., Williams, D., Widmer, M. (1992) Effect of soluble rhu IL-1 and TNF receptors on hemodynamics, metabolism, hematology, and circulating levels of inflammatory cytokines in a non-human primate model of endotoxin shock. Meeting of the International Society of Endotoxin Shock. August 16-20, Vienna, Austria. MacVittie, T.J., Farese, A.M., Kirschner, K.F., Patchen, M.L., Myers, L.A. (1992) Therapeutic efficacy of rhIL-6 in a nonhuman primate model of high dose, sublethal, radiation-induced marrow aplasia. The 34th Annual Meeting for the American Society of Hematology. Dec. 4-8, Anaheim, CA. MacVittie, T.J., Kittell, C.L., Kirschner, K.F., Farese, A.M., Agosti, J., Williams, D.E., Widmer, M. (1993) Preclinical efficacy of soluble rhuIL-1 and TNF receptors on hemadynmaic, metabolic, and circulating levels of inflammatory cytokines in a nonhuman primate model of endotoxin shock. Keystone Symposia on Molecular and Cellular Biology. Cytokines and Cytokine Receptors:From Cloning to the Clinic. Jan 31Feb. 7, Keystone, CO. MacVittie, T.J., Farese, A.M., Patchen, M.L. (1993) Cytokine therapy in preclinical models of radiation-induced bone marrow aplasia. 41st Annual Meeting of Radiation Research Society. Mar 20-25. Dallas, TX. MacVittie, T.J., Farese, A.M., Kirschner, K.F., Kittell, C.L., Patchen, M.L., Waisman, Y., Eichacker, P.Q., Natanson, C., Widmer, M., Agosti, J., Williams, D.E. (1993) Prophylaxis and therapy in preclinical models of lethal gram negative sepsis and sublethal endotoxic shock:Use of recombinant canine G-CSF and soluble receptors for IL-1 and TNF. Second Consensus Development Conference on the Treatment of Radiation Injury. April 14-17, Bethesda, MD MacVittie, T.J., Farese, A.M., Patchen, M.L. (1993) Cytokine therapy in preclinical models of radiation-induced bone marrow aplasia.Second Consensus Development Conference on the Treatment of Radiation Injury. April 14-17, Bethesda, MD
Page 19 of 31
Ann M. Farese
26. 27.
28.
29. 30.
31.
32.
33.
34.
35.
36.
MacVittie, T.J., Farese, A.M., Patchen, M.L. (1993) Cytokine therapy in preclinical models of radiation-induced marrow aplasia. 8th Symposium Molecular Biology of Hematopoiesis. July 9-13, Basel, Switzerland. McKearn, J.P., Baum, C.M., Olins, P.O., Paik, K.K., Klover, J.A., Donnelly, A., Bell, L.D., Klein, B.K., Bauer, C.S., Goldberg, S.B., Abegg, A., MacVittie, T.J., Farese, A.M. (1993) Synthetic IL-3 receptor agonists with selective biologcial activity. 8th Symposium Molecular Biology of Hematopoiesis. July 9-13, Basel, Switzerland. MacVittie, T.J., Farese, A.M., Patchen, M.L., Myers, L.A. (1993) Comparative therapeutic efficacy of combination recombinant human IL-6 and IL-3 cytokine protocols in a primate model of radiation-induced marrow aplasia. 22nd Annual Meeting of the International Society for Experimental Hematology. Aug 22-27, Rotterdam, The Netherlands. Exp. Hematol. 21:592a, 1171. Williams, D.E., Farese, A., MacVittie, T.J. (1993) PIXY321, but not GM-CSF plus IL-3, promotes hematopoietic reconstitution following lethal irradiation. 35th Annual Meeting of the American Society of Hematology. Dec. 3-7, St. Louis, MO. MacVittie, T.J., Farese, A.M., Patchen, M.L. (1993) Comparative therapeutic efficacy of combination IL-6 and IL-3 cytokine protocols in a primate model of radiation-induced marrow aplasia. Serono Symposium on Platelets and Cellular Support in Clinical Oncology. Sept. 30 - Oct 2, Arlington, VA. Williams, D.E., Park, L.S., Farese, A., MacVittie, T.J. (1994) Preclinical and clinical biology of PIXY321. 23rd Annual Keystone Symposia on Molecular and Cellular Biology. Hematopoiesis. Jan 4-11, Breckenridge, CO. The Journal of Cellular Biochemistry Suppl 18A, 4. Eichacker, P.Q., Waisman, Y., Natanson, C., Farese, A., Hoffman, W., Wilson, L., Banks, S.M., MacVittie, T.J. (1994) Recombinant G-CSF increases endotoxin clearance, reduces serum TNF levels and improves survival in a canine model of septic shock. Third International Congress on the Immune Consequences of Trauma, Shock, and SepsisMechanisms and Therapeutic Approaches. 2-5 March, Munich, Germany. Intensive Care Medicine 20:558a, S142. Myers, L.A., MacVittie, T.J., Farese, A.M. (1994) Preclinical evaluation of leukemia inhibitory factor (LIF) in health and radiation treated non-human primates. Conference on Interleukin-6-type Cytokines, Sponsored by The New York Academy of Sciences, June 19-22, Poznan, Poland. MacVittie, T.J., Dobson, M.E., Farese, A.M., Virca, G.D., Sims, J.E., Dower, S.K., Cross, A., Hoover, D., Kirschner, K.F., Agosti, J., Williams, D.E., Widmer, M.B. (1994) Comparative efficacy of soluble rhuIL-1 receptors type I and II in modulating the hemodynamic, metabolic and inflammatory cytokine response in a nonhuman primate model of endotoxin shock. 23rd International Meeting of the Society of Experimental Hematology. Aug 21-25, Minneapolis, MN. Exp Hematol. 22:25a, 683. McKearn, J.P., Bauer, C., Klein, B., Olins, P., Paik, K., Donnelly, A., Kahn, L.E., Thomas, J., Hood, W., Staten, N., Mori, N., Baum, C.M., Farese, A., Herodin, F., MacVittie, T. (1994) Evaluation of synthetic cytokine agonist of the Human IL-3 receptor with significantly improved activity relative to native IL-3. The 36th Annual Meeting of the American Society of Hematology. Dec 3-7, Nashville, TN. Blood 84:Suppl 1 422a, 1672. Grab, L.B., Farese, A.M., Hunt, P., Herodin, F., Matlick, D.R., MacVittie, T.J. (1995) In
Page 20 of 31
Ann M. Farese
37.
38.
39.
40.
41.
42.
43.
44.
vitro and ex vivo marrow-derived clonogenic activity from normal and recombinant human (r-Hu) megakaryocyte growth and development factor (MGDF)-treated primates. American Society for Bone Marrow Transplantation. Jan 26-28, Keystone, CO. MacVittie, T.J., Herodin, F., Farese, A.M., Grab, L.B., Baum, C., McKearn, J.P. (1995) Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and rhG-CSF. American Society for Bone Marrow Transplantation. Jan 26-28, Keystone, CO. MacVittie, T.J., Farese, A.M., Grab, L.B., Hunt, P. (1995) Effect of delayed administration of recombinant human megakaryocyte growth and development factor on hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia. The 24th Annual Meeting for the Society for Experimental Hematology, Aug 2731, Dusseldorf, Germany. Exp Hematol 23:311a, 830. MacVittie, T. J., Farese, A. M., Grab, L. B., Baum, C., McKearn, J. P. (1995) Stimulation of multilineage hematopoietic recovery in a nonhuman primate, bone marrow aplasia model by a multifunctional agonist of human IL-3 and G-CSF receptors. 37th Annual Meeting for the American Society of Hematology. Dec 1-5, Seattle, WA. MacVittie, T.J., Farese, A.M., Herodin, F., Grab, L.B., Baum, C., McKearn, J.P. (1996) Stimulation of multilineage hematopoietic recovery in a nonhuman primate, bone marrow aplasia model by Synthokine (SC55494) and rhG-CSF or Myelopoietin. The Immunocompromised Surgical Patient: Mechanisms and Therapy in Trauma and Burns. Jan 21-24, Snowbird, UT. Giri, J.G., Kahn, L., Staten, N., Wood, D., Favara, J., Pegg, L., Thomas, J., Burnette, B., Hirsh, J., Huynh, M., Monahan, J., Farese, A., MacVittie, T., Baum, C., McKearn, J. (1996) An engineered novel factor for expansion and development of platelet producing cells. 25th Annual Keystone Symposia on Molecular and Cellular Biology. Molecular Regulation of Platelet Production. Feb 24-28, Taos, NM. MacVittie, T.J., Farese, A.M., Grab, L.B. Vigneulle, R.M., Dacquel, L., Stead, R. B. (1996) Efficacy of PEG-rHuMGDF in nonhuman primate models of radiation-induced myelosuppression or myeloablation with autologous bone marrow transplantation. Satellite symposium to European Bone Marrow Transplantation Meeting. Mar 3-7, Vienna, Austria. McKearn, J., Monahan, J., Hood, W., Donnelly, A., Ellison, S., Kahn, S., Giri, J., Grab, L., Farese, A., MacVittie, T., (1996) Myelopoietin- A multifunctional chimeric protein family. 25th Annual Meeting for the International Society for Experimental Hematology, 23-27 August, New York, NY. Exp Hematol 24:712a, 1154. Giri, J.G., Kahn, L.E., Staten, N.R., Wood, D.C., Favara, J.P., Abegg, A.L., Pegg, L.E., Thomas, J.W., Huynh, M.S., Monahan, J., Farese, A., MacVittie, T., Baum, C.M., Blystone, L.W., McKearn, J.P. (1996) An engineered novel factor for expansion and development of platelet producing cells. 25th Annual Meeting for the International Society for Experimental Hematology, 23-27 August, New York, NY. Exp Hematol 24:259a, 1072.
Page 21 of 31
Ann M. Farese
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
Giri, J.G., Kahn, L.E., Doshi, P.D., Minstor, N.I., Streeter, P.R., Pegg, L.E., Thomas, J.W., Abegg, A. L., Favara, J.P., Staten, N.R., Huynh, M.S., Monahan, J.B., Wood, D.C., Burnette, B.L., Villani-Price, D., Farese, A. M., MacVittie, T.J., Smith, W.G., McKearn, J.P. (1996) Promegapoietin, an engineered chimeric growth factor for platelet producing cells. 38th Annual Meeting for the American Society of Hematology, Dec 6-10, Orlando, FL. Blood 88:351a Kahn, L.E., Blystone, L.W., Villany-Price D., Smith, W.G., Farese, A.M., MacVittie, T.J., Lazzaro, N.C., Bloss, J.L., Komocsar, W.J., McKearn, J.P., Giri, J.G. (1996) In vitro and in vivo biology of an engineered novel factor for expansion and development of platelet producing cells. 38th Annual Meeting for the American Society of Hematology, Dec 6-10, Orlando, FL. Blood 88:351a MacVittie, T.J., Farese, A.M., Davis, T.A., Lind, L.B., McKearn, J.P. (1996) Mobilization of CD34+ and hematopoietic clonogenic cells in normal nonhuman primates using myelopoietin, synthokine, G-CSF and synthokine plus G-CSF. 38th Annual Meeting for the American Society of Hematology, Dec 6-10, Orlando, FL. Blood 88:642a Malech, H., Jordan, C., Whiting-Theobald, N., Lu, F., Vowells, S.J., Farese, A. M., Lind, L., Davis, T., Rosenzweig, M., Lyman, S., MacVittie, T.J. (1997) flt-3L with G-CSF effectively mobilizes CD34+ cells to peripheral blood and enhances cycling of the most primitive CD38+ subset in the monkey. 19th Annual Phagocyte Workshop, April 25, Washington, D.C. MacVittie, T.J., Farese, A.M., Lind, L.B., Stead, R.B., Hunt, P., J. P. McKearn. (1997) Effect of combination cytokines or chimeric cytokine receptor agonists on hematopoietic regeneration following radiation-induced myelosuppression. 19th Annual Phagocyte Workshop, Apr 25, Washington, D.C. Giri, J.G., Smith, W.G., Kahn, L.E., Wood, D.C., Staten, N.R., Abegg, A. L., Donnelly, A., Pegg, L.E., Thomas, J.W., Villani-Price, D., Lind, L., Farese, A. M., MacVittie, T.J., McKearn, J.P. (1997) Promegapoietin, a chimeric growth factor for platelet restoration. 10th Symposium: Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, July 2-6, Hamburg, Germany. Smith, W.G., MacVittie, T. J., Farese, A. M., Davis, T. D., Lind, L. B., McKearn, J. P. (1997) Mobilization of progenitor cells into peripheral blood in normal nonhuman primates using myelopoietin.10th Symposium: Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, July 2-6, Hamburg, Germany. Kahn, L.E., Farese, A.M., MacVittie, T.J., Strauss-Schoenberger, J.M., Minster, N.I., Lind, L.B., McKearn, J.P., Streeter, P.R. (1997) Progenipoietin-G promotes in vivo expansion of hematopoietic progenitor cells in mice and in nonhuman primates. 39th Annual Meeting for the American Society of Hematology, Dec. 5-9, San Diego, CA. Blood 90:58a, 248. MacVittie, T.J., Farese, A. M., Lind, L.B., Smith, W.G., Streeter, P., McKearn, J. P. (1997) Progenipoietin-G stimulates hematopoietic recovery following myelosuppression. 39th Annual Meeting for the American Society of Hematology, Dec. 5-9, San Diego, CA. Blood 90:581a, 2586. Giri, J.G., Smith, W.G., Kahn, L.E., Streeter, P., Minster, N., Baum, C., Lind, L., Farese, A.M., Lin, J., Roecklein, B., MacVittie, T.J., McKearn, J.P. (1997) Promegapoietin, a chimeric growth factor for megakaryocyte and platelet production. 39th Annual Meeting
Page 22 of 31
Ann M. Farese
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
for the American Society of Hematology, Dec. 5-9, San Diego, CA. Blood 90:580a, 2583. MacVittie, T.J., Farese, A. M., Lind, L.B., Smith, W.G., McKearn, J. P. (1997) Abbreviated schedule of myelopoietin administration stimulates multilineage hematopoietic regeneration after X-irradiation. 39th Annual Meeting for the American Society of Hematology, Dec. 5-9, San Diego, CA. Blood 90:186b, 3559. McKearn, J., Giri, J., Welply, J., Caparon, M., Polazzi, J., Kahn, L., Shieh, J.J., Hood, W., Monahan, J., Grabbe, E., Abegg, A., Donnelly, A., Feng, Y., Baganoff, M., McWherter, C., Goldberg, S., Zurfluh, L., Smith, W., Klein, B., Farese, A., MacVittie, T.(1997) Structure and function of myelopoietins, a family of hematopoietic growth factors. 39th Annual Meeting for the American Society of Hematology, Dec. 5-9, San Diego, CA. Blood 90:58a, 249. Roskos, L., Stead, R., Harker, L., Cebon, J., Basser, R., Begley, G., Farese, A., MacVittie, T., Tomita, D., Paine, T., Cheung, E. (1997) A cytokinetic model of platelet (PLT) production and destruction following administration of PEG-rHuMGDF. 39th Annual Meeting for the American Society of Hematology, Dec. 5-9, San Diego, CA. Blood 90:171a, 755. Rosenzweig, M., MacVittie, T., Harper, D., Hempel, D., Glickman, R., Johnson, R. P., Farese, A., Lind, L., Lyman, S., Theobald, N., Linton, G., Jordan, C., Malech, H. (1998) Efficient and persistent gene marking of hematopoietic progenitor cells in nonhuman primates. Keystone Symposia: Gene Therapy Strategies for Hematopoietic Cells. Jan 10-15, Lake Tahoe, NV. MacVittie, T.J., Farese, A. M., Smith, W.G., McKearn, J. P. (1998) New generation growth factors (GF) for the treatment of radiation-induced myelosuppression: chimeric GF receptor agonists. International Conference on Diagnosis and Treatment of Radiation Injury, 31 Aug- 3 Sept. Rotterdam, The Netherlands Klein, B., Thomas, J., Klover, J., Shieh, J.J., Donnelly, A., Abegg, A., Dacquel Smith, L., Webster, H., Farese, A., MacVittie, T., McKearn, J. (1998) Comparison of daniplestim and human interleukin-3 impact of structure on functional activity. 40th Annual Meeting for the American Society of Hematology, Dec 4-8, Miami, Fl. Blood 92:174b Woulfe, S. L., Streeter, P.R., Kahn, L.E., Minster, N.I., MacVittie, T. J., Farese, A.M., McKearn, J.P. (1998) Expansion of functionally competent multi-lineage hematopoietic cells using the novel chimeric hematopoietic growth factor, progenipoietin. 40th Annual Meeting for the American Society of Hematology, Dec 4-8, Miami, Fl. Blood 92:377a Siegel, N., Villani-Price, D., Abrams, M., Galluppi, G., Abegg, A., Burnette, B., Finn, R., Frazier, R., Heeren, R., Sobacke, S., Woodward, H., Giri, J., Kahn, L., Pegg, L., Staten, N., Braford-Goldberg, S., Summers, N., Smith, W., Farese, A., MacVittie, T., McKearn, J. (1998) Pharmacokinetic differences observed for assorted promegapoietin molecules in rhesus monkey studies. 40th Annual Meeting for the American Society of Hematology, Dec 4-8, Miami, Fl. Blood 92:175b Smith, W.G., Giri, J.G., Abegg, A., Donnelly, A., Paik, K., Hood, W. P., Monahan, J.B., Welply, J., Polazzi, J., Caparon, M., Klein, B., Farese, A.M., Lind, L.B., Dacquel Smith, L., MacVittie, T.J., McKearn, J.P. (1998) Preclinical pharmacology of the myelopoietin leridistim, a multifunctional agonist of IL-3 and G-CSF receptors. 40th Annual Meeting for the American Society of Hematology, Dec 4-8, Miami, Fl. Blood 92:380a MacVittie, T.J., Farese, A.M., Dacquel Smith, L., Casey D.B., Smith, W.G., Woulfe, S.
Page 23 of 31
Ann M. Farese
65.
66.
67.
68.
69.
70.
71.
72.
73.
L., Streeter, P.R., McKearn, J.P. (1998) Member of the progenipoietins, a family of chimeric Flt-3 ligand and G-CSF receptor agonists mobilize hematopoietic progenitor cells with different kinetics and efficiency in nonhuman primates. 40th Annual Meeting for the American Society of Hematology, Dec 4-8, Miami, Fl. Blood 92:682a Doshi, P.D., Klein, B.K., Streeter, P.R., Kahn, L.E., MacVittie, T.J., Farese, A.M., Fleming, W.H., McKearn, J.P., Woulfe, S.W. (1999) Progenipoietin, a chimeric growth factor which mobilizes hematopoietic progenitors and dendritic cells. 4th Congress European Haematology Association, Jun 9-12, Barcelona, Spain. Haematologica 84:79 King, A.G., Pelus, L.E., Farese, A., MacVittie, T. (1999) Rapid hematopoieticprogenitor cell (HPC) mobilization induced by a single dose of truncated Gro (SB251353) in rhesus monkeys. 28th Annual Meeting of the International Society for Experimental Hematology, July 10-14, Monte Carlo, Monaco. Exp Hematol 27:113, abstract 292. MacVittie, T. J., Farese, A.M. (1999) Cytokine-based treatment of radiation injury: Is there a potential benefit following low level radiation (LLR) exposure? International Conference on Low-level Radiation Injury and Medical Countermeasures, Nov 8-10. Bethesda, MD Li, X., Hood. W. F., Klelin, B. K. Polazzi, J. O., Welply, J. K., Smith, W. G., Shieh, J-J. J., Abegg, A. L., Farese, A. M., Casey, D. B., Vigneulle, R. M., MacVittie, T. J., McKearn, J. P., Monahan, J. B. (1999) The biological role of the IL-3 receptor agonist in myelopoietin-mediated tyrosine phosphorylation and proliferation in vitro and hematopoietic recovery in vivo. 41th Annual Meeting for the American Society of Hematology, Dec 3-7, New Orleans, LA Blood 94:472a, abstract 2104 MacVittie, T.J., Casey D.B., Kahn, L. E., Farese, A.M., Redinger, C. J., Woulfe, S. L. (1999) Progenipoietin, a chimeric Flt-3 and G-CSF receptor agonist, mobilizes type 1 and type 2 phenotypic dendritic cells in rhesus macaques. 41th Annual Meeting for the American Society of Hematology, Dec 3-7, New Orleans, LA Blood 94:48a, abstract 201. Orlic, D., Farese, A.M., Anderson, S., MacVittie, T.J., Bodine, D.M. (2000) Expansion of rhesus monkey hematopoietic stem cells in response to administration of leridistim or progenipoietin (ProGP). 29th Annual Meeting of the International Society for Experimental Hematology. July 8-11, Tampa, FL. Exp Hematol 28:93, abstract 199. Choi, U., MacVittie, T.J., Farese, A.M., Malech, H.L., Horwitz, ME. (2001) Persistent low level retrovirus gene marking of hematopoietic stem cells following nonmyeloablative chemotherapy conditioning in a rhesus macaque model. 4th Annual Meeting of the American Society of Gene Therapy. May 30-Jun3, Seattle, WA. Mense, M., Borschel, R., MacVittie, T., Farese, A., Hoover, D., (2001) Immunohistochemical findings in Brucella melitensis induced hepatitis in rhesus monkeys. American College of Veterinary Pathologist and American Society of Veterinary Clinical Pathology Meeting. Dec 1-5, Salt Lake City, UT. Ladd, A., Farese, A., Redinger, C., Douek, D., Mann, D., Woulfe, S., MacVittie, T. (2001) Radiation-induced T cell deficiencies can be abbreviated with administration of the dual growth factor receptor agonist progenipoietin. 43rd Annual Meeting for the American Society of Hematology, Dec 1-6, Orlando, FL., Blood 98:296a, abstract 1247.
Page 24 of 31
Ann M. Farese
74.
75.
76.
77.
78.
79.
80. 81. 82.
83.
84.
85.
Koopman, G., Haaksma, A.G.M., Niphuis, H., Farese, A. M., Casey, D.B., MacVittie, T. J., Kahn, L.E., Woulfe, S. L., Heeney, J. L. (2001) Progenipoietin, a chimeric FLT-3 and G-CSF receptor agonist, mobilizes type 1 and type 2 dendritic cells in SIV infected rhesus macaques. Dutch Society for Immunology. Dec 20-21, Noordwijkerhout, The Netherlands. Poliakova, L., Pirone, A., Farese, A., Farney, A., Ross, D., MacVittie, T. (2003) Adult tissue-derived side population (SP) cells in the pancreas, liver and bone marrow of the rhesus macaque. 6th International Congress of the Cell Transplant Society. April 2-6, Atlanta, GA. Poliakova, L., Pirone, A., Farese, A., Bartlett, S., MacVittie, T., Farney, A.,(2003) Presence of non-hematopoietic side population cells in the adult human and non-human primate pancreas. 9th Congress of the International Pancreas and Islet Transplant Association. July 8-11, Dublin, Ireland. Crook J. L., MacVittie, T. J., Farese, A. M., Shumaker, J. M., Cheng, X., Meisenberg, B. R., Takebe, N. (2003) Human brain endothelial cells (HuBECs) support ex vivo expansion of human cord blood CD34+ cells, as well as adult human bone marrow CD34+ cells. 45th ASH Meeting, Dec 6-9, San Diego, CA Brenner, S., Choi, U., Whiting-Theobald, N., Linton, G., Kang, E., Rudikoff, A. G., Farese, A. M., MacVittie, T. J., Horwitz, M.E., Malech, H.L. (2003) Insertional analyses in rhesus monkey blood cells after non-myeloablative hematopoietic stem cell marking with a RD114 MFGS-gp91phox vector for treatment of X-linked chronic granulomatous disease: pre-clinical safety studies. 45th ASH Meeting, Dec 6-9, San Diego, CA MacVittie, T.J., Farese, A.M., Jackson, W. (2004) Defining the full potential of supportive care and cytokine therapy in the post radiation accident environment. National Council on Radiation Protection and Measurements Fortieth Annual Meeting, Apr 14-15, Crystal City, VA MacVittie, T.J., Farese, A.M,, Jackson, W. (2004) Defining the full potential of supportive care and cytokine therapy in the post radiation accident environment. First Canadian Therapeutics Congress, June 4-6, Winnipeg, Manitoba MacVittie, T.J., Farese, A.M,, Jackson, W. (2004) Establishing a treatment protocol for severely irradiated personnel in the radiation accident scenario: The evolving preclinical data base. European Radiation Research Society, Aug 24-28, Budapest, Hungary. Lee, D., Tsvetnitsky, V., Kodihalli, S., Sharif, W., Farese, A., Veirs, M., MacVittie, T., Vlahovich, S., Stewart, D. (2005) Evaluation of granulocyte-macrophage colony stimulating factor for acute radiation syndrome. 2005 CRTI Summer Symposium, 20-22 Jun, Gatineau, Quebec. Takebe, N., Cheng, X., Farese, A.M., Welty, E., Meisenberg, B., MacVittie, T.J. (2005) Human brain endothelial cells (HUBEC) can expand both human bone marrow and cord blood SCID-repopulating cells (SRC) through cell contact rather than soluble factors. Dec 10-13, Atlanta, GA Blood 106:15a, abstract #36 Takebe, N., MacVittie, T.J., Cheng, X., Farese, A.M., Welty, E., Meisenberg, B., (2005) Attenuation of surface CXCR4 down-regulation in human cord blood HSC during ex vivo expansion using the HUBEC co-culture system. Dec 10-13, Atlanta, GA Blood 106:311a, abstract #1068 MacVittie, T.J., Farese, A.M., Veirs, M., Fasano, A. (2007) New Generation Therapeutics: Potential Medical Countermeasures Against Radiation-induced
Page 25 of 31
Ann M. Farese
86. 87.
88.
89.
90.
91.
92. 93.
94.
95. 96.
97.
Gastrointestinal or Hematopoietic Syndromes. 10th Annual Force Health Protection Conference, Aug 4-10, Louisville, KY Lerma, F., Lui, B., Wang, Z., Yu, C., Koshy, M., Farese, A., MacVittie, T., (2008) Online Re-planning using direct machine parameter optimization: A non-human primate lung irradiation study. Med. Phys., 35:6, 2711. Ossetrova, N.I., Farese, A. M., MacVittie, T.J., Sandren, D.J., Gallego, S., Blakely, W. F., (2008) Improvement of radiation dose assessment using multiple-protein expression and hematological profiles. Partial-body Radiation Diagnostic Biomarkers and Medical Management of Radiation Injury Workshop. 5-6 May, Bethesda, MD Plett, A., Walters, A., West, E., Nguyen, N-T., Chua, H-L, Kohlbacher,K., Farese, A., MacVittie, T., Orschell, C.M., (2008) Hematopoietic parameters in lethally-irradiated C57BL/6 mice receiving radiomitigating does of granulocyte-colony stimulating factor (GCSF), pegGCSF, or pretreatment with amifostine. 54th Annual Meeting of the Radiation Research Society, 21-25 Sept, Boston, MA. Proceedings PS4546, pp 90. Plett A, Walters A., West E , Kohlbacher K, Nguyen N-T, Chua H-L, Juliar B, Farese A, Katz B, MacVittie TJ, Orschell CM, (2008) Feed and water as vehicles for efficacious deliver of antibiotics to lethally-irradiated mice: comparison of ciprofloxacin versus doxycycline and neomycin. 54th Annual Meeting of the Radiation Research Society, 2125 Sept, Boston, MA. Proceedings Abstract:PS3553, pp 92. Blakely WF, Ossetrova NI, Farese AM, MacVittie TJ, Sandren DJ, DiCarlo-Cohen AL, Goans RE. (2008) Early-response biological dosimetry using hematological profile. 54th Annual Meeting of the Radiation Research Society, 21-25 Sept, Boston, MA. Proceedings Abstract:PS3551, pp 91. Gelfond D, Shea-Donohue T, McFarland MC, Zhao A, Sun R, Booth C, Potten C, Farese AM, Fasano A, MacVittie TJ. (2008) Non human primate (NHP) model of radiationinduced gastrointestinal syndrome with emphasis on structural, biological and functional changes in the intestinal mucosa. 54th Annual Meeting of the Radiation Research Society, 21-25 Sept, Boston, MA. MacVittie, T.J., Farese, A.M., (2008) Medical Countermeasures Against the Acute Hematopoietic Syndrome: The best treatment available today. Medical Countermeasures for Radiation Injury Conference. Aug. 17-21, New Dehli, India MacVittie, T.J., Farese, A.M., Gelfond, D. Cohen, M., McFarland, D., Potten, C., Booth, C. (2008) Medical Countermeasures Against The Acute Hematopoietic And Gastrointestinal (GI) Syndromes: The Best Treatment Available Today. ICRB Nov 1012, Jaipur, India. Higgins, A., Bennett, A., Cohen, M., Farese, A., MacVittie, T. (2009) Immune Reconstitution In The Non-Human Primate (NHP) Following Total Body Irradiation (TBI). Keystone Symposia, Immunologic Memory and Host Defense, Feb 8-13, Keystone, CO. Lerma, F., MacVittie, T., Farese, A., Wang, A., Amin, P. (2009) Late survival post acute total body irradiation in the rhesus macaque with bone marrow sparing. Med. Phys. 36:6, 2734. MacVittie, T.J., Farese, A.M., Cohen, M.V., Booth, C., Potten, C., McFarland, E., (2009) Evaluation and treatment of ARS damage in the rhesus macaque: establishing an ARS animal research platform. 37th Annual Mtg of European Radiation Research Society, Aug 26-29, Prague, CZ. Proceedings Abstract:140 Shea-Donohue T, Fasano A, Zhao A, Notari L, Stiltz J, DeVito J, McFarland E, Farese
Page 26 of 31
Ann M. Farese
98.
99.
100.
101.
102. 103.
104.
105.
106. 107.
A, MacVittie T. (2009) An acute radiation syndrome (ARS) nonhuman primate (NHP) research platform: prolonged gastrointestinal (GI) dysfunction observed in NHPs surviving the acute heme and GI syndromes. 55th Annual Radiation Research Meeting, Oct 3-7, Savannah, GA. Proceedings Abstract: 6.48, pp145-146. Orschell, C.M., Plett, A., Yamin, M., Brines, M., Katz, B., Juliar, B., Farese, A., MacVittie, T.Booth, C., (2009) ARA290 is an efficacious radiomitigator of both the hematopoietic and gastrointestinal syndromes of the acute radiation syndrome. Morbidity and mortality of lethally irradiated mice undergoing periodic blood sampling. 55th Annual Radiation Research Meeting, Oct 3-7, Savannah, GA. Proceedings Abstract: 6.45, p145 Plett, A., Sampson, C., West, E., Nguyen, N., Chua, H.L., Farese, A., Parker, J., Katz, B., MacVittie, T., Juliar, B., Orschell, C.M. (2009) Relationship between dose of total body irradiation (TBI) and temporal changes in plasma cytokines and hematopoietic cells. 55th Annual Radiation Research Meeting, Oct 3-7, Savannah, GA. Proceedings Abstract: 1.46, p67 King, G.L., Villa, V., Rahman, A., Mitchell, J., Farese, A.M., MacVittie, T.J., Blakely, W.F. (2009) ARS Severity-Response and “Early Humane Endpoint� Scoring System for Nonhuman Primate Radiation Dose-Response Model. 55th Annual Radiation Research Meeting, Oct 3-7, Savannah, GA, Proceedings Abstract: 4.37, p111 Ossetrova NI, Farese AM, MacVittie TJ, Cohen M, Rahman A, Sandgren DJ, Gallego S, Blakely WF. (2009) Early-phase and Organ-specific Protein Biomarkers for Radiation Dose and Injury Assessment. 55th Annual Radiation Research Meeting, Oct 3-7, Savannah, GA, Proceedings Abstract: 4.56, p70 McFarland EC, Gibbs A, Cohen MV, Farese AM, MacVittie TJ. (2009) Clinical Signs of the Acute and Prolonged Radiation-Induced Gastrointestinal Syndromes in Rhesus Macaques. 60th AALAS National Mtg. Nov 8-12, Denver, CO Ossetrova NI, Farese AM, MacVittie TJ, Cohen M, Sandgren DJ, Blakely WF. (2010) Protein Biomarkers for Enhancement of Radiation Dose and Injury Assessment. International Symposium on EPR Dosimetry and Dating (EPR). Oct. 10-14, Mandelieula-Napoule, France. William F. Blakely, W.F., Ossetrova NI,, Rahman A,, Cohen M.V., Farese AM, Sandgren DJ, MacVittie TJ (2010) Early-response biological dosimetry using hematological profile - NHP dose response. 56th Annual Meeting of Radiation Research Society, Sept 25-29, Maui, HI. Proceedings Abstract: PS3.19, p102 and MS608, p 46 MacVittie, T.J., Farese, A.M., Cohen, M.V., Bennett, A., Jackson, W. III, Ossetrova, N.I., Blakely, W.F. (2011) A Nonhuman Primate Research Platform: Development of Biomarkers for Hematopoietic, GI, and Lung Sequelae. International Biodosimetry Research Symposium. Armed Forces Radiobiology Research Inst. 18-19 April, Bethesda, MD. MacVittie, T.J., Farese, A.M., Cohen, M.V., Jackson, W. III (2011) Cytokines in the Treatment of Radiation Injury. Radiation Countermeasure Symposium, Armed forces Radiobiology Research Institute. 15 June, Bethesda, MD. MacVittie, T.J., Farese, A.M., Bennett, A., McFarland, E. Tudor, G., Tudor, J., SheaDonohue, T., Gelfond, D. Ward, A., Cohen, M.V., Fasano, A., Potten, C., Booth, C. (2011) The Lethal Dose Response Relationship and Time Course of Morbidity and Mortality in a Nonhuman Primate Model of the Acute Gastrointestinal (GI) SubSyndrome of the Acute Radiation Syndrome. Presented at 14th International Congress of
Page 27 of 31
Ann M. Farese
108.
109.
110.
111.
112. 113.
114.
115.
116.
117.
Radiation Research. 28 Aug – 1 Sept., Warsaw, Poland. Garofalo, M.C., Farese, A.M., Ward, A.A., Taylor-Howell, C.L., Cohen, M.V., Gibbs, A.M., MacVittie, T.J. (2011) AEOL-10150 (C45H56C15MnN12) as a Mitigator of Radiation-Induced Lung Damage in a Rhesus Macaque Model. Presented at the 14th International Congress of Radiation Research, 28 August-1 Sept., Warsaw, Poland. Shea-Donohue, T., Notari, L., Yan S., Zhao, A., Vanuytsel T., Bennett A., Ward, A., Tudor, G., Booth C., Fasano A., Farese, A., MacVittie T. (2011) Long-lasting impairment of mucosal barrier function in the post-irradiation period impairs mucosal recovery and results in a prolonged GI syndrome. Presented at the 14th International Congress of Radiation Research, 28 August-1 Sept., Warsaw, Poland. Sampson, C., Plett, A., Chua, H.L., Mandar, J., Yonehiro, G., Devens, B., Lenden, K., Katz, B., MacVittie, T.J., Farese, A. M., Orschell, C. M. (2011) Single injection of Maxy-G34 is as effective as 2 or 3 injections to increase 30-day survival of lethallyirradiated mice. Presented at the 14th International Congress of Radiation Research. 28 August – 1 Sept., Warsaw, Poland. Cui, W., Garofalo, M., Ward, A., Flinn, C., Farese, A., MacVittie, T. (2012) Decreased Nrf2 signaling contributes to radiation-induced lung fibrosis in a non-human primate model. Keystone Symposia: Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics, Big Sky, MT, March 30-April 4. MacVittie, T.J., Farese, A.M. (2012) Treatment of potentially lethal radiation-induced acute radiation syndrome: Evidence-based support for medical countermeasures. International Radiation Protection Association. Glasgow, Scotland, UK, May 13-15. Yan, S., Notari, L., Vanuytsel, T., Zhao, A., Bennett, A., Tudor, J., Tudor, G., Booth, C., Farese, A.M., MacVittie, T.J., Shea-Donohue, T. (2012) possible role of barrier dysfunction and inflammation in the alteration of the stem cell microenvironment. Presented at the Digestive Disease Week, 19-22 May, San Diego, CA. Garofalo, M.C., Ward, A.A., Smith, C. P., Cui, W., Flinn, C.D., Meletakos, G. M., Cohen, D.M., Taylor-Howell, C. L.. Farese, A. M., MacVittie, T.J. (2012) Dose dependent survival following whole thorax lung irradiation in a nonhuman primate model of radiation induced pulmonary injury. 58th Annual Meeting of Radiation Research Society, 29 Sept – 4 Oct, San Juan, Puerto Rico, Proceedings Abstract:PS6-05, pp128. Shea-Donohue T, Notari L, Vanuytsel T, Yan S, Zhao A, Bennett A, Farese A, Tudor G, Booth C, MacVittie TJ. (2012) Characterization of the prolonged post-irradiation gastrointestinal (GI) syndrome in mice. 58th Annual Meeting of Radiation Research Society, 29 Sept – 4 Oct, San Juan, Puerto Rico, Proceedings Abstract:PS5-46, pp126. Meineke, V., Shapiro, A., Dörr, H.D., Gräßle, D., Farese, A. M., Garofalo, M., Bennett, A., MacVittie, T.J., (2012) Linking the Human Response to Unplanned Radiation and Treatment to the Nonhuman Primate Response to Controlled Radiation and Treatment: A New Approach to Compare Human and Animal Data. European Radiation Research Meeting, 15-19 Oct., Vietri sul Mare, Italy. Jones, J.W., Bennett, A., Farese, A.M., MacVittie, T.J., Kane, M.A. (2013) Biomarker discovery for radiation-induced tissue damage via un-targeted mass spectrometry based metabolomics. Annual Meeting American Society of Mass Spectrometry, 9-13 Jun, Minneapolis, MN.
Page 28 of 31
Ann M. Farese
118.
MacVittie, TJ., Bennett, A., Farese, A.M., Blakely, W., Ossetrova, N., Smith, C., Gibbs, A. (2013) The influence of G-CSF administration on the absolute neutrophil: lymphocyte count (ANC:ALS) ratio in nonhuman primates (NHP) following exposure to total-(T) or partial-body irradiation (PBI).ConRad 2013 Global Conference on Radiation Topics, 1-6 May, Munich, GR.
Major Invited Speeches National 1. Farese, A.M., "Current Therapeutic Treatments Following Radiation Exposure." Cellular Immunology Seminar Series, Wilford Hall USAF Medical Center, Lackland AFB, December 1988, San Antonio, TX 2. Farese, A.M., "Radiation Injury and the Use of Recombinant Growth Factors as Treatment", Clinical Pathology Continuing Education Lecture Series, NIH, Feb., 1989, Bethesda, MD 3. Farese, A.M., "The Effect of Cytokine Administration on Neutrophil Function." AFRRI Off-site Program Review, August 1992, Harpers Ferry, WV 4. Farese, A.M., "Stimulation of canine neutrophils by recombinant human interleukin-8 (rhIL-8) or phorbol 12-myristate 13-acetate (PMA) following in vivo administration of either recombinant canine granulocyte (rcG-CSF) or granulocyte-macrophage colonystimulating factor (rcGM-CSF)." 21st Annual Meeting of the International Society for Experimental Hematology. July 26-30, 1992, Providence, RI 5. Farese, A.M., "The functional activity of canine PMNs following in the in vivo administration of recombinant canine granulocyte colony-stimulating factor in the normal and septic canine." Monsanto-Searle Research Co. Jan 14, 1993 St. Louis, MO 6. Farese, A.M., "Stimulation of canine neutrophils by recombinant human interleukin-8 (rhIL-8) or phorbol 12-myristate 13-acetate (PMA) following in vivo administration of either recombinant canine granulocyte (rcG-CSF) or granulocyte-macrophage colonystimulating factor (rcGM-CSF)." AFRRI Institute Seminar Series. Feb 22, 1994. Bethesda, MD 7. Farese, A.M., "Therapeutic efficacy of the combined administration of either recombinant human interleukin-6 and rh-granulocyte colony stimulating factor or rhgranulocyte-macrophage colony stimulating factor in a primate model of radiationinduced marrow aplasia." 23rd International Meeting of the Society of Experimental Hematology. Aug 21-25, 1994, Minneapolis, MN 8. Farese, A.M., "Therapeutic efficacy of recombinant human megakaryocyte and development factor", Amgen Meeting, Dec 1, 1994 Nashville, TN 9. Farese, A.M., "Modulation of megakaryocytopoiesis in normal and sublethally irradiated nonhuman primates by recombinant human megakaryocyte growth and development factor (r-HuMGDF)", First Annual Meeting for the American Society for Blood and Marrow Transplantation: "Translation Research in Blood and Marrow Transplantation". Plenary Session. January 1995, Keystone, CO 10. Farese, A.M., “Single and combined cytokine therapy, treatment of bone marrow aplasia, Amgen, Inc., May 3, 1995, Thousand Oaks, CA 11. Farese, A.M., "Enhancement of hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia by the combined administration of
Page 29 of 31
Ann M. Farese
12. 13.
14. 15. 16.
17. 18. 19.
20. 21. 22. 23. 24. 25.
recombinant human megakaryocyte growth and development factor and granulocyte colony stimulating factor". Amgen Meeting, May 19, 1995, Los Angeles, CA Farese, A.M., "Therapeutic efficacy of recombinant human megakaryocyte and development factor", Invited seminar ProNeuron, Inc., July1995, Rockville, MD Farese, A.M., “Efficacy of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) alone and in combination with recombinant human granulocyte colony stimulating factor (rhG-CSF)”, The Immunocompromised Surgical Patient: Mechanisms and Therapy in Trauma and Burns, Jan 21-24, 1996, Snowbird, UT. Farese, A.M., “Efficacy of Competitive Cytokines in a Primate Model of Myelosuppression.” Invited seminar Amgen, Inc., April 15, 1996, Thousand Oaks, CA Farese, A.M., “Efficacy of Competitive Cytokines in a Primate Model of Myelosuppression”, Invited seminar at Monsanto, Company, Sep 27, 1996. St. Louis, MO Farese, A.M., “The stimulation of canine neutrophils by recombinant human interleukin-8 or phorbol 12-myristate 13-acetate (PMA) following in vivo administration of either recombinant canine granulocyte (rcG-CSF) or granulocyte-macrophage colony stimulating factor (rcGM-CSF)”, 19th Annual Phagocyte Workshop, April 25, 1997, Washington, DC Farese, A.M., “Progenipoietins, chimeric agonists of Flt-3 and the G-CSF receptors, stimulate multilineage hematopoietic recovery in myelosuppressed nonhuman primates”, 40th Annual Meeting for the American Society of Hematology, Dec 4-8, 1998, Miami, FL Farese, A.M., “Rhesus macaque models of myelosuppression: Potential therapies”, Invited seminar Eli Lilly, Oct 31, 2001, Indianapolis, IN Farese, A.M., “Defining the full potential of supportive care and cytokine therapy in the post radiation accident environment.” International Conference, “Frontiers in Pharmacology and Toxicology”, Assessing the Efficacy and Safety of New Drugs, Aug. 28-31, 2006, Chicago, IL Farese, A.M., “Medical Management Used Alone is an Effective Medical Countermeasure Against the Lethal Effects of Total Body Irradiation (TBI)”,10th Annual Force Health Protection Conference, Aug 4-10, 2007, Louisville, KY Farese, A.M., “Treatment of the ARS “, BARDA: Blood and Tissue-Related Medical Countermeasures Working Group. Feb.19, 2008 Washington, DC Farese, A.M., “Neupogen as a MCM Against the Hematopoietic Acute Radiation Syndrome (H-ARS): The best treatment protocol available today”, FDA, Public Health Security Action team (PHSAT). 27 Oct, 2011, Silver Spring, MD Farese, A.M., “The Hematopoietic Acute Radiation Syndrome: Radiation quality and animal model development”. FDA, Pubic Health Security Action Team (PHSAT). 9 Nov, 2011, Silver Spring, MD. Farese, A.M., “FDA animal rule and development of G-CSF for hematopoietic ARS.” BARDA/NIAID Symposium, “Developing radiation medical countermeasures for licensure, lessons learned and paths forward”, Jan 24-25, 2013, Bethesda, MD Farese, A.M., As Study Director presented efficacy data for filgrastim, based on treatment in an animal model of radiation-induced myelosuppression. Joint Meeting of the Medical Imaging Drugs Advisory Committee and Oncologic Drugs Advisory Committee Meeting, convened to discuss the safety and efficacy of currently approved leukocyte growth factors (LGFs) as potential treatments for radiation-induced
Page 30 of 31
Ann M. Farese
26. 27. 28.
myelosuppression associated with a radiological/nuclear incident. May 3, 2013, Silver Spring, MD Farese, A.M., “Why G-CSF?” AFRRI Sponsored Symposium, “Military Radiobiology Research in the 21st Century: Threats, Triage and Treatment” August 27, 2013, Bethesda, MD Farese, A.M., “The Findings and Impact of an FDA Study Audit.” Invited seminar at SNBL, Oct 8, 2013, Everett, WA Farese, A.M., “GLP Implementation in the Academic Environment.” Invited seminar at Wake Forest University, Oct. 22, 2013, Winston Salem, NC.
International 1. Farese, A.M., "Effect of delayed administration of recombinant human megakaryocyte growth and development factor on hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia." 24th Annual Meeting of the International Society for Experimental Hematology. Aug 27-Sept 1, 1995, Dusseldorf, Germany. 2. Farese, A.M., "Enhancement of hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia by the combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony stimulating factor." 24th Annual Meeting of the International Society for Experimental Hematology. Aug 27-Sept 1, 1995, Dusseldorf, Germany. 3. Farese, A.M., "Megakaryocyte growth and development factor: Preclinical Efficacy”, Joint Congress, European Society for Haemapheresis: 10th Congress, Deutsche Gesellschaft Für Transfusionsmedizin und Immunhämatologie: 28th Kongreß. September 1995, Vienna, Austria 4. Farese, A.M., “Progenipoietin-G, an engineered chimeric agonist for flt-3 and G-CSF receptors stimulates multilineage hematopoietic recovery following radiation-induced myelosuppression.”International Conference on Diagnosis and Treatment of Radiation Injury, 31 Aug- 3 Sept. 1998, Rotterdam, The Netherlands 5. Farese, A.M., “An abbreviated schedule of leridistim induces multilineage recovery in myelosuppressed rhesus primates.” 28th Annual Meeting of the International Society for Experimental Hematology, July 10-14, 1999, Monte Carlo, Monaco 6. Farese, A.M., “Progenipoietins, chimeric agonists of Flt-3 and the G-CSF receptors, stimulate multilineage hematopoietic recovery in myelosuppressed nonhuman primates”, Invited seminar at BPRC, Jan 12, 2000, Rijwijk, The Netherlands 7. Farese, A.M., “Medical countermeasures against the acute hematopoietic and gastrointestinal (GI) syndromes”, 37th Annual Meeting of the European Radiation Research Society, Aug 26-29, 2009, Prague, CZ
Page 31 of 31